Matt Abernethy

CIK: 0001724097

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (19.2%)

Position reduction

Option Exercises (M)8 (30.8%)

Derivative conversions

Awards (A)6 (23.1%)

Compensation grants

Other (G, F, J, C, D, …)7 (26.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NBIX

NEUROCRINE BIOSCIENCES INC

Officer

FATE

FATE THERAPEUTICS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (26 total)

NBIX
NEUROCRINE BIOSCIENCES INC
Sep 14, 2026
Sale(S)
Direct
2.3K shares at avg. $157.20$363K
NBIX
NEUROCRINE BIOSCIENCES INC
Sep 11, 2026
Tax Payment(F)
Direct
2.7K shares at avg. $156.22$423K
NBIX
NEUROCRINE BIOSCIENCES INC
Sep 11, 2026
Award(A)
Direct
5K shares-
FATE
FATE THERAPEUTICS INC
Jun 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
87.9K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Mar 4, 2026
Gift(G)
Direct
2.2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Exercise(M)
Direct
2.6K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Exercise(M)
Direct
2.2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
1.2K shares at avg. $124.12$150K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
1.4K shares at avg. $124.12$172K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Award(A)
Direct
10K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
5.4K shares at avg. $124.12$668K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2026
Tax Payment(F)
Direct
1.2K shares at avg. $123.10$142K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2026
Exercise(M)
Direct
2.1K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Jan 31, 2026
Tax Payment(F)
Direct
1.4K shares at avg. $136.06$186K
NBIX
NEUROCRINE BIOSCIENCES INC
Jan 31, 2026
Exercise(M)
Direct
2.4K shares-
FATE
FATE THERAPEUTICS INC
May 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
110K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Exercise(M)
Direct
2.6K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Sale(S)
Direct
1.4K shares at avg. $116.85$158K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Exercise(M)
Direct
2.2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Sale(S)
Direct
1.2K shares at avg. $116.87$141K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2025
Award(A)
Stock Option
Direct
45.5K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2025
Award(A)
Restricted Stock Unit
Direct
8.5K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 10, 2025
Sale(S)
Direct
980 shares at avg. $118.27$116K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 8, 2025
Exercise(M)
Direct
1.9K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Jan 31, 2025
Sale(S)
Direct
1.3K shares at avg. $152.87$196K

		Type	Shares	Price		Ownership
Sep 14, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	2,311	$157.20	$363,285	Direct
Sep 11, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	2,709	$156.22	$423,200	Direct
Sep 11, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Award(A)	5,020	-	$0	Direct
Jun 12, 2026	FATE FATE THERAPEUTICS INC	Award(A) Stock Option (Right to Buy)	87,900	-	-	Direct
Mar 4, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Gift(G)	2,249	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,566	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,241	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,210	$124.12	$150,185	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,385	$124.12	$171,906	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Award(A)	9,968	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	5,378	$124.12	$667,517	Direct
Feb 12, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,151	$123.10	$141,688	Direct
Feb 12, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,133	-	$0	Direct
Jan 31, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,368	$136.06	$186,130	Direct
Jan 31, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,437	-	$0	Direct
May 29, 2025	FATE FATE THERAPEUTICS INC	Award(A) Stock Option (Right to Buy)	110,000	-	-	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,566	-	-	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	1,352	$116.85	$157,979	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,241	-	-	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	1,206	$116.87	$140,944	Direct
Feb 12, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Award(A) Stock Option	45,538	-	-	Direct
Feb 12, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Award(A) Restricted Stock Unit	8,534	-	-	Direct
Feb 10, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	980	$118.27	$115,909	Direct
Feb 8, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	1,860	-	-	Direct
Jan 31, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	1,283	$152.87	$196,136	Direct

1-25 of 26 transactions

About ABERNETHY MATT

ABERNETHY MATT (SEC CIK 0001724097) files insider reports with the SEC as Chief Financial Officer of NEUROCRINE BIOSCIENCES INC (NBIX) and Director of FATE THERAPEUTICS INC (FATE).

Signal8 holds 10 ownership filings by ABERNETHY MATT (1 Form 3, 9 Form 4), filed between Feb 4, 2025 and Sep 15, 2026. Those filings report 26 transactions, from Jan 31, 2025 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ABERNETHY MATT's filings is in SAN DIEGO, CA.

Recent filings by ABERNETHY MATT

Sep 14, 2026: Open-market sale of NBIX shares (Form 4, code S).
Sep 11, 2026: Tax withholding of NBIX shares (Form 4, code F).
Sep 11, 2026: Grant or award of NBIX shares (Form 4, code A).
Jun 12, 2026: Grant or award of FATE derivative securities (Form 4, code A).
Mar 4, 2026: Gift of NBIX shares (Form 4, code G).

Other insiders filing for NEUROCRINE BIOSCIENCES INC (NBIX)

ROBERTS EIRY, Chief Medical Officer
Onyia Jude, Chief Scientific Officer
Lippoldt Darin, Chief Legal Officer
Keswani Sanjay Chandru, Chief Medical Officer
GORMAN KEVIN CHARLES, Director
Gano Kyle, Chief Executive Officer

How to read Form 4 transaction codes